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Abstract
Background: Acinetobacter baumannii is an opportunistic human pathogen often associated with life-threatening
infections in the immunocompromised and the critically ill. Strains are often multidrug-resistant (MDR) and due to
the lack of new synthetic antimicrobials in development for treatment, attention is increasingly focused on natural
compounds either as stand-alone or adjunctive agents. Curcumin (CCM) is a natural polyphenol found in turmeric and
isolated from the plant, Curcuma longa. Curcumin has been found to possess many biological properties, including
antibacterial activity. In this study the antimicrobial activity of CCM and synergistic effects with epigallocatechin gallate
(EGCG) against multidrug-resistant strains of A. baumannii were investigated and assessed via checkerboard and
time-kill assays.
Results: The MIC of CCM was >256 μg/mL against all strains of A. baumannii whilst those for EGCG ranged from
128-1024 μg/mL. In checkerboard studies synergy was observed against 5/9 isolates, with an additive effect noted in
the remaining 4. The addition of EGCG reduced the MIC of CCM by 3- to 7-fold, with the greatest interaction resulting
in a CCM MIC of 4 μg/mL. Time-kill curves indicated that a CCM-EGCG (1:8 and 1:4) combination was bactericidal with
a 4 to 5-log reduction in viable counts after 24 h compared to the most effective polyphenol alone.
Conclusions: This study demonstrates that despite little antibacterial activity alone, CCM activity is greatly enhanced in
the presence of EGCG resulting in antibacterial activity against MDR A. baumannii. The combination may have a
potential use in medicine as a topical agent to prevent or treat A. baumannii infections.
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Background
Acinetobacter baumannii is a non-fermentative Gram-
negative bacterium that has emerged as a troublesome
opportunistic human pathogen associated with life-
threatening infections in the immunocompromised and
critically ill [1]. It is a cause of bloodstream, respiratory,
surgical and burn wound infections, often associated with
medical devices. In recent years multi-drug resistant (MDR)
strains have disseminated worldwide [2]. A. baumannii is
intrinsically resistant to many antimicrobial compounds but
also has a remarkable capacity to capture and sustain
antimicrobial resistance determinants [2]. MDR strains
are able to evade the effects of most antibiotics through a
combination of enzymatic inactivation (β-lactamases,
aminoglycoside modifying enzymes), impermeability (porin
loss), chromosomal mutations and active efflux of drugs.
Due to the lack of new synthetic antimicrobials in
development for the treatment of MDR Gram-negative
infections, attention is increasingly focused on natural
compounds either as stand-alone or adjunctive therapies.
These include plant polyphenols such as those found in tea
e.g. catechins and spices e.g. curcumin. Curcumin (CCM) is
a diphenolic compound, commonly used in the form of
turmeric throughout central and Eastern Asia as a
spice and/or colouring agent in foodstuffs and textiles. A
number of potential health benefits have been associated
with CCM including anti-neoplastic, anti-inflammatory
and anti-oxidant effects [3]. Studies have also revealed that
CCM may have antimicrobial activity against both Gram-
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positive (Streptococcus mutans) [4] and Gram-negative
bacteria (Helicobacter pylori) [5].
The antibacterial effects of CCM have also been shown
to be affected when combined with other antimicrobials.
Synergy has been observed when combined with oxacillin
and ampicillin against meticillin-resistant Staphylococcus
aureus [6] but antagonism when used with ciprofloxacin
against Salmonella typhi [7].
Epigallocatechin-3-gallate (EGCG) is a polyphenol found
in green tea, which like CCM, has been linked with health
benefits and has significant antimicrobial activity against
some MDR pathogens [8,9]. Previous studies have
also shown that A. baumannii is inhibited by EGCG
at concentrations between 78-625 μg/mL [10] and that
the compound may act as an inhibitor of chromosomal
penicillinase in S. aureus [11].
The potential for polyphenols to be used together
against MDR Gram-negative bacteria was demonstrated
previously, whereby potent synergy was observed when
epicatechin was combined with theaflavin against A.
baumannii and Stenotrophomonas maltophilia [12].
The bioavailability of natural compounds such as poly-
phenols and curcumin has been previously investigated
and found to be in some cases their ‘Achilles heel’. Several
studies have reported that although polyphenols penetrate
effectively into various tissues [13] their bioavailability
is poor [14] and it is difficult to achieve adequate
concentrations for antimicrobial activity in mammalian
models [15]. This may be a facet of their ability to bind to
proteins [16] although many polyphenols are also rapidly
metabolised in mammals [17]. If polyphenols are not
absorbed before the small intestine, they are readily
hydrolysed to simple phenolics by bacteria in the human
microflora [18] further reducing their systemic bio-
availability. Although phase 1 clinical trials have found
that high doses (12 g/day) of systemic CCM are safe [19],
the use of polyphenols as antimicrobials is likely to
be limited to use as topical agents. The toxicity of
EGCG was limited to minor skin irritation in mamma-
lian models [20] at high concentrations and no adverse
effects were seen with preparations containing up to
500 mg/Kg/day.
In this study we present data on the activity of CCM
alone and in combination with EGCG against a well char-
acterised collection of MDR A. baumannii clinical isolates.
Methods
Chemicals reagents and media
Curcumin powder (≥90% purity) extracted from Curcuma
longa was purchased from the Cayman Chemical
Company (Michigan, USA). Epigallocatechin gallate
(≥95% purity) was donated by Unilever PLC (Bedford, UK).
All growth media (Iso-Sensitest broth) was purchased from
Thermo Scientific (Basingstoke, UK), sterilised and made
up locally according to the manufacturer’s instructions.
Bacterial strains
Nine Acinetobacter baumannii isolates were studied. These
included the antibiotic susceptible type strain ATCC 19606
and 8 MDR clinical isolates. These have been extensively
characterised previously and were chosen to be representa-
tive of UK epidemic clones (OXA-23 clones 1, 2, ‘Burn’)
and/or exhibit resistance to colistin, tigecycline or produce
metallo-β-lactamases (NDM enzymes) [21] Properties of
the strains are detailed in Table 1. All isolates were stored
at -70°C in microbank vials (Thermofisher, UK) and thawed
prior to their use.
Determination of minimum inhibitory concentrations
Minimum inhibitory concentrations (MICs) were deter-
mined in corning 96-well microtitre plates (Corning,
Amsterdam, The Netherlands). MICs of EGCG, CCM
and combinations of both polyphenols were determined
against all nine isolates according to British Society of
Antimicrobial Chemotherapy (BSAC) susceptibility
testing guidelines [22]. Doubling dilutions of CCM
and EGCG stock solutions were added to horizontal
wells in individual microtitre plates resulting in final
concentrations ranging from 256-0.5 μg/mL (CCM) and
1024-2 μg/mL (EGCG). Equal volumes of A. baumannii
Table 1 Resistant determinants and sources of multidrug-resistant clinical isolates of Acinetobacter baumannii
Isolate Properties Isolate source
AB 19606 Antibiotic Susceptible type Strain. National Collection of type cultures
AB 14 MDR PFGE defined UK OXA-23 clone 1 OXA-23-like carbapenemase producer. Dr J Turton, Public Health England, Colindale, UK
AB 16 MDR PFGE defined UK OXA-23 clone 2 OXA-23 carbapenemase producer. Dr J Turton, Public Health England, Colindale, UK
AB 186 MDR PFEG defined UK ‘burn’ strain, OXA-23 producer. Dr J Turton, Public Health England, Colindale, UK
AB 202 Tigecycline-resistant strain UK OXA-23 clone 1 isolate. Barts Health NHS Trust, London, UK
AB 205 Colistin resistant UK OXA-23 clone 1 isolate. Barts Health NHS Trust, London, UK
AB 292 MDR PFGE-defined OXA-23-like carbapenemase producer. Barts Health NHS Trust, London, UK
AB 306 MDR NDM-1 carbapenemase producer. Barts Health NHS Trust, London, UK
AB 308 MDR NDM-2 carbapenemase producer. S. Gottig, Goethe Universistat, Frankfurt, Germany
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(105 CFU) in Iso-Sensitest broth were added to each well.
After incubation at 37°C for 24 h in air, wells were
checked for turbidity and the MIC recorded as the lowest
concentration where no bacterial growth was observed.
All microtitre assays were performed in triplicate and
mean values presented.
Determination of in vitro synergy of CCM-EGCG
combinations
Synergy between CCM and EGCG was assessed in checker-
board assays, with doubling concentrations of CCM in
vertical wells (256-4 μg/mL) and EGCG in horizontal wells
(1024-1 μg/mL). Wells were inoculated with 105 CFU of
each A. baumannii isolate, incubated and analysed for
growth as above. All assays were repeated in triplicate.
Where the MIC was not reached, the concentration 1
dilution above the highest tested was used in assessing the
strength of antimicrobial interactions.
Synergy between CCM and EGCG was determined by
calculation of the Fractional Inhibitory Concentration
Index (FICI) as previously described [1] whereby:
FICI ¼ MICof CompoundAincombination
MICof CompoundAalone
þMICof Compound B incombination
MICof CompoundBalone
Synergy between the two compounds was defined as a
FICI of ≤ 0.5, > 0.5-1.0 as an additive effect, > 1.0-4 as an
intermediate effect and a value of > 4 suggestive of
antagonism between the two compounds [23].
Time-kill assays
Time-kill assays were undertaken using the antibiotic
susceptible type strain (AB19606) and MDR isolate
AB292 to determine the bactericidal activity of CCM,
EGCG and a CCM-EGCG combination. Isolate AB292
was selected for use in time-kill as it is harbours a common
MDR resistance profile, belongs to an epidemic clone
(UK OXA-23 clone 1), but had similar MICs for
CCM and EGCG as A. baumannii ATCC 19606. A 1
in 1000 dilution of an overnight culture of AB19606
and AB292 in Iso-Sensitest broth (106 CFU/mL) was
performed before the addition of CCM (0.25 × MIC),
CCM (0.5 × MIC), EGCG (0.5 × MIC), EGCG (1 × MIC)
or a combination of CCM-EGCG in a 1:4 ratio (w/w) and
1:8 ratio (w/w). Cultures (10 mL in universal bottles) were
incubated at 37°C under continuous agitation for 24 h. At
time intervals of 0, 2, 4, 6 and 24 h post inoculation,
samples (100 μl) were collected, serially diluted and
plated onto Iso-Sensitest agar. All inoculated plates were
incubated at 37°C for 20 h before colonies were counted.
Time-kill curves (CFU/mL v time) were plotted using
GraphPad software. A difference of > 2 log10 CFU/mL
between the single polyphenol and the polyphenols in
combination at 24 h was used to determine synergy [24].
Results and discussion
The MICs of CCM and EGCG alone and in combination
are shown in Table 2. CCM had little antibacterial activity
against any of the A. baumannii isolates even at a concen-
tration of 256 μg/mL. Due to the solubility of CCM in
water based media, concentrations >256 μg/mL could not
be tested. When calculating the FICI a CCMMIC one dilu-
tion above the maximum concentration tested was used
(Table 2). MICs of EGCG ranged from 128–1024 μg/mL.
The antimicrobial activity of CCM was much lower
against A. baumannii than those reported for S. aureus
(MIC = 125-250 μg/mL) [6] and H. pylori (5-50 μg/mL)
[5]. This could reflect variations in the growth media,
differences in lipopolysaccharide (LPS) or cell wall
architecture as well as penetration and transport of CCM
across the Gram-negative outer membrane, issues well
known to mediate resistance in A. baumannii [25].
Several mechanisms for the antibacterial activity of
CCM have been proposed including disruption of core
metabolic pathways involved in folic acid metabolism
(shikimate dehydrogenase) [5] and bacterial cell division
(FtsZ) [26].The MICs of EGCG against the A. baumannii
isolates used in our study were also higher than those
previously reported [10] although it should be noted that
the isolates tested in our study belonged to extensively
resistant clones.
In combination tests, increased antibacterial activity was
observed, with MICs for the combination being signifi-
cantly lower than those for individual compounds. The
addition of EGCG reduced the MIC of CCM by up to 3 -7
fold and was as low as 4 μg/mL for several isolates. Synergy
Table 2 Minimum inhibitory concentrations (MICs) of
curcumin, epigallocatechin gallate and combinations of
both compounds and fractional inhibitory concentration
indexes (FICIs) versus Acinetobacter baumannii
Isolate MICs in monotherapy
(μg/mL)
MICs in combination
(μg/mL)
FICIs
CCM EGCG CCM EGCG
AB 19606 >256 1024 4 256 0.258 (S)
AB 14 >256 1024 4 512 0.508 (Ad)
AB 16 >256 1024 32 512 0.56 (Ad)
AB 186 >256 512 64 128 0.38 (S)
AB 202 >256 1024 64 512 0.63 (Ad)
AB 205 >256 1024 4 512 0.508 (Ad)
AB 292 >256 1024 4 256 0.258 (S)
AB 306 >256 128 4 32 0.258 (S)
AB 308 >256 256 4 64 0.258 (S)
MICs were within +/-1 dilution on replicate tests. CCM = curcumin,
EGCG = epigallocatechin gallate, S = synergy, Ad = additive effect.
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between the two polyphenols was observed against five
isolates (FICI ≤ 0.5) including one of the OXA-23 clone 1
isolates and the two NDM producers. An additive effect
was observed with the remaining 4 isolates (Table 2). These
results indicate that combinations of CCM and EGCG
synergistically inhibit the growth of A. baumannii and that
no antagonism occurs. This adds to previous research
which showed synergy between natural compounds includ-
ing tea polyphenols [12], where the addition of epicatechin,
a compound with no antimicrobial activity against A.
baumannii potentiated the activity of theaflavin.
The FICI as a measure of synergistic activity has limita-
tions and more conservative limits of interpretation have
been suggested [27]. The susceptibility breakpoint index
(SBPI) may be a more useful parameter to assess positive
interactions and the clinical usefulness of antimicrobial
combinations [28]. However, as there are no breakpoints
for EGCG and CCM susceptibility for A. baumannii or any
other bacterial species, it was not possible to calculate an
SBPI in this study. Therefore time-kill assays were used as a
more robust method of assessing synergy.
In time time-kill assays with the compounds used in 1:4
and 1:8 w/w (CCM:EGCG) ratios versus ATCC 19606 and
AB292, a 4-5 log10 CFU/mL decrease was observed with
the combination compared to the most effective polyphenol
alone (Figure 1 and Figure 2) at 24 h. The combination had
a sustained bactericidal effect up to and beyond 24 h post
exposure whilst EGCG alone was only bacteriostatic, with
regrowth observed after 6 hours exposure.
Although the mechanism for the antimicrobial synergy
between CCM and EGCG has not been determined, it may
involve disruption of the Gram-negative outer membrane
combined with inhibition of essential proteins. Polyphenols
including EGCG have a low affinity to bind LPS [29] but
are able to act as pro-oxidants in the presence of metal
ions. This may lead to increased H2O2 production and the
formation of a hydroxyl radical, a mechanism shown
previously to promote apoptosis in eukaryotic tumour
cells [30] and outer membrane disruption/lysis of
Klebsiella pneumoniae and Escherichia coli [31]. A possible
explanation for the synergy between CCM and EGCG
could therefore be disruption of the outer membrane via
EGCG-led formation of H2O2 facilitating the entry of
CCM into the cell. There is also evidence that antioxidants
may protect each other from degradation [32,33] but
further studies are required to investigate whether this
phenomenon contributes to the enhanced antimicrobial
activity of CCM in combination with EGCG”.
Although both EGCG and CCM-EGCG combinations
have antimicrobial properties against MDR A. baumannii,
both compounds have poor bioavailability. Due to this
and the current solubility issues of CCM, any use would
be limited to topical treatments. Although alone MICs are
high, their clinical use as topical agents may still be
possible as very high concentrations can be achieved
locally [34]. In combination the concentrations required
for antibacterial activity in-vitro are significantly lower and
may be more readily obtained. The combination could have
potential for the treatment and prevention of traumatic or
burn wound infections and also as a coating on medical
devices, surgical dressings, antimicrobial clothing [35] or as
preservatives in foods to prevent spoilage.
The poor solubility of CCM in water is a limitation in
determining in-vitro activity and may underestimate its
biological activity. The development of water-soluble de-
rivatives will be important in maximising the potential
of this natural compound and previous studies have
tried to address this [36]. Water-soluble curcumins have
been developed as potential anticancer therapies al-
though more cost effective and efficient methods are still
needed for the extraction and modification of CCM. Al-
though synergy between antimicrobial agents is import-
ant, the effect of antimicrobial combinations on bacterial
killing and their ability to reduce antimicrobial resistance
is crucial. Future studies should look into the effects of
CCM in combination with other topical antimicrobial
agents to further assess their potential as adjuncts for
the treatment of MDR bacterial infections.
Conclusions
Our study has shown that a combination of CCM and
EGCG has an enhanced antimicrobial activity against
Figure 1 Time-kill curve of Acinetobacter baumannii (ATCC 19606)
versus CCM, EGCG and combinations of both compounds.
Figure 2 Time-kill curve of Acinetobacter baumannii (AB292)
versus of CCM, EGCG and combinations of both compounds.
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multidrug-resistant Acinetobacter baumannii. This research
suggests that the combination could be developed as
an effective topical antimicrobial agent for the treatment
and control of MDR Gram-negative infections in health
and medicine.
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